Syndax Pharmaceuticals (SNDX) Capital Expenditures (2015 - 2025)

Syndax Pharmaceuticals (SNDX) posted quarterly Capital Expenditures of $56000.0 for Q4 2025, up 300.0% quarter-over-quarter from $14000.0 in Q4 2018.

Analysis

Syndax Pharmaceuticals (SNDX) Capital Expenditures (2015 - 2025) Analysis & Trends

Syndax Pharmaceuticals' Capital Expenditures history runs 5 years deep, the most recent figure standing at $56000.0 for Q4 2025.

In Q4 2025, Capital Expenditures changed N/A year-over-year to $56000.0; the TTM figure through Dec 2025 stood at $70000.0 (up 400.0% YoY), while the FY2025 annual figure was $187000.0, changed N/A from the prior year.
Capital Expenditures for Q4 2025 stood at $56000.0, up from $14000.0 in the prior quarter.
The five-year high for Capital Expenditures was $56000.0 in Q4 2025, with the low at $56000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	37.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	2.29 Mn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	25.02 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	34.68 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	251.02 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	6.26 Mn
10	Syndax Pharmaceuticals	1.83 Bn	1.28 Bn	60.67 Mn	-

Historic Data

Download Data